The treatment of immune TTP is anchored around therapeutic plasma exchange, which serves to remove autoantibodies and ultra-large von Willebrand factor multimers, and to replenish ADAMTS13 [11]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.